DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/CJC-1295 (no DAC)
Growth hormoneRx required

CJC-1295 (no DAC)

Also known as: Mod GRF 1-29 · Modified GRF(1-29) · Tetrasubstituted GRF

Modified GHRH(1-29) with four amino-acid substitutions and NO drug-affinity complex — short half-life variant.

C
Grade C
Animal studies only
Human studies0
PubMed citations1
Routesubcutaneous
Regulatory (US)Rx required
Last verified2 days ago

Mechanism of action

Tetrasubstituted analog of sermorelin (GHRH 1-29). The four modifications protect against DPP-4 and trypsin cleavage without the albumin-binding DAC moiety, giving a short half-life measured in minutes.

Evidence summary

0
Human studies
1
PubMed citations
0
Clinical trials
C
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Research chemical; available through some compounding pharmacies.

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

No indexed ClinicalTrials.gov studies for CJC-1295 (no DAC). This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.